Roche Holding Ltd Is Betting Billions on This New Blockbuster

Roche's move to pay as much as $2 billion for Seragon is a major vote of confidence for an unproven therapy approach

Jul 2, 2014 at 5:57PM

Roche (NASDAQOTH:RHHBY) rarely does expensive early stage deals, relying instead upon its deep proprietary pipeline of oncology drug candidates. So when the company commits itself to $725 million upfront and $1 billion more in milestones (to say nothing of the hundreds of millions that will be required for clinical trials) for a new cancer drug approach, investors would do well to pay attention. When that new approach concerns breast cancer, an area where Roche is particularly strong, it's all the more interesting.

Enter Seragon
Roche announced Wednesday that it is acquiring Seragon, a privately held biotech recently spun off when Johnson & Johnson (NYSE:JNJ) acquired Aragon Pharmaceuticals. Like Aragon, Seragon's focus is in hormone-related cancers, but focused on breast cancer instead of prostate cancer.

Roche is agreeing to pay $725 million in upfront cash, with contingent milestone payments potentially totaling another $1 billion. By way of comparison, Medivation (NASDAQ:MDVN), which has Xtandi approved, on the market, and expected to generate over $500 million in revenue this year, carries an enterprise value of just under $6 billion while Pharmacyclics, Johnson & Johnson's partner on Imbruvica, has a nearly identical just-under-$6 billion enterprise value.

What Roche is getting
In acquiring Seragon, Roche is getting Seragon's portfolio and R&D expertise in selective estrogen receptor degraders (or SERDs) – a potentially new class of oral medications that can address the 60% to 70% of breast cancers that are hormone receptor-positive.

Targeting estrogen receptors is not a new approach, as selective estrogen receptor modulators (or SERMs) like tamoxifen have been around for a while, as have drugs that directly target estrogen (like aromatase inhibitors). Seragon's platform appears to take it up a notch. Not only do these molecules act like "glue in the lock" for breast cancer cells, they can actually modify the receptor in such a way that the cell eliminates it entirely.


That latter point could be key, as research has indicated that hormone receptor-positive cancers are so "addicted" to estrogen signaling that the receptor will mutate in such a way that it can be active even without estrogen to bind to it. SERDs, then offer the potential of a highly potent, highly selective (and therefore possibly safer) treatment for these breast cancer types, either as monotherapy or part of a combination.

Sergaon's lead compound ARN-810 is now in Phase I testing.

There *will* be others
No good idea goes uncopied in Big Pharma and I cannot imagine that the industry will look at Roche shelling out so much money for an early stage company and not take a look at the SERD space themselves. Look no further than immuno-oncology and drugs like PD-1/PDL-1 antibodies – at least a half-dozen companies are under way with competing versions (including Roche), so there's no way Roche will have this all to itself.

I'm aware of one other company actively look at SERDs (Radius), but this is definitely a case where absence of proof should not be read as proof of absence. Large pharmaceutical companies in particular are known to be cagey about talking about the mechanism of action for drugs in Phase I or preclinical testing.

I'd also note that Medivation is looking to try Xtandi in breast cancer – both in androgen receptor-positive types and estrogen receptor-positive or progesterone receptor-positive types as well. My understanding of Xtandi is that it does not destroy the receptor as Seragon's compounds seem to, and that could be an important differentiating factor in long-term efficacy. Either way, it's far too soon to say.

The bottom line
It strikes me as interesting that Johnson & Johnson did not choose to buy all of Aragon's assets when it could; perhaps J&J was uncomfortable paying what management wanted for those assets at the time, or perhaps J&J doesn't have ambitions to take on the breast cancer space. Either way, if Seragon's compounds/technology go on to do great things, I expect Johnson & Johnson investors might want an explanation.

As for Roche, any time a company goes against its long-demonstrated operating philosophy it is a reason for pause. I think Roche is making a risky bet here, but I also believe that Roche deserves the benefit of the doubt when it comes to understanding the breast cancer space and recognizing a game-changing therapy approach when they see it. While I don't want to dismiss the risk with a glib "it's only money, and Roche can afford it", the reality is just that – this is a risky move, but it is one that Roche can easily afford and one that could extend Roche's leadership in breast cancer for more than a decade to come.

Like dividend stocks like Roche? Try this list of top stocks
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.

Stephen D. Simpson, CFA owns shares of Roche. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.

 


Compare Brokers